➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
Dow
McKesson
Express Scripts

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 9,750,788

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,750,788
Title:Non-acylated exendin-4 peptide analogues
Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
Inventor(s): Kadereit; Dieter (Frankfurt am Main, DE), Lorenz; Katrin (Frankfurt am Main, DE), Evers; Andreas (Frankfurt am Main, DE), Haack; Torsten (Frankfurt am Main, DE), Wagner; Michael (Frankfurt am Main, DE), Henkel; Bernd (Frankfurt am Main, DE), Lorenz; Martin (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE)
Assignee: SANOFI (Paris, FR)
Application Number:14/569,299
Patent Claims:see list of patent claims

Details for Patent 9,750,788

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Mylan Pharms Inc SEMGLEE insulin glargine INJECTABLE;INJECTION 210605 001 2020-06-11   Start Trial SANOFI (Paris, FR) 2033-12-13 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 003 2018-10-19   Start Trial SANOFI (Paris, FR) 2033-12-13 RX search
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 002 2018-10-19   Start Trial SANOFI (Paris, FR) 2033-12-13 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 001 2018-10-19   Start Trial SANOFI (Paris, FR) 2033-12-13 RX search
Novo FIASP PENFILL insulin aspart SOLUTION;SUBCUTANEOUS 208751 003 2018-03-06   Start Trial SANOFI (Paris, FR) 2033-12-13 RX search
Novo FIASP FLEXTOUCH insulin aspart SOLUTION;SUBCUTANEOUS 208751 002 2018-03-06   Start Trial SANOFI (Paris, FR) 2033-12-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Mallinckrodt
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.